CompletedPhase 1

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

United States16 participantsStarted 2026-02-06

Plain-language summary

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine. The goals of the trial are to learn: * What happens to different forms of MK-1167 in a healthy person's body over time * About the safety of MK-1167 and if people tolerate it

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Is in good health * Has a body mass index (BMI) ≥18 and ≤ 32 kg/m\^2, inclusive Exclusion Criteria: * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases * Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Area Under the Curve from Time 0 to Infinity (AUC0-inf) of MK-1167

Timeframe: At designated time points (up to approximately 21 days)

Maximum Plasma Concentration (Cmax) of MK-1167

Timeframe: At designated time points (up to approximately 21 days)

Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) of MK-1167

Timeframe: At designated time points (up to approximately 21 days)

Trial details

NCT IDNCT07334860

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05-20

View on ClinicalTrials.gov More Healthy trials

Plain-language summary

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Area Under the Curve from Time 0 to Infinity (AUC0-inf) of MK-1167

Timeframe: At designated time points (up to approximately 21 days)

Maximum Plasma Concentration (Cmax) of MK-1167

Timeframe: At designated time points (up to approximately 21 days)

Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) of MK-1167

Timeframe: At designated time points (up to approximately 21 days)